Alnylam Pharmaceuticals | ALNY - Cost Of Sales

Stock Price
328.14
Daily Change
-3.10 -0.94%
Monthly
-22.33%
Yearly
18.81%
Q1 Forecast
327.65

Alnylam Pharmaceuticals reported $200.15M in Cost of Sales for its fiscal quarter ending in September of 2025.





Cost Of Sales Change Date
Acadia Pharmaceuticals USD 21.65M 913K Sep/2025
Agios Pharmaceuticals USD 1.68M 22K Sep/2025
Alnylam Pharmaceuticals USD 200.15M 57.2M Sep/2025
Amgen USD 1.79B 128M Dec/2025
BioMarin Pharmaceutical USD 144.93M 10M Sep/2025
Incyte USD 99M 20.23M Sep/2025
Ionis Pharmaceuticals USD 2.34M 1.81M Sep/2025
Moderna USD 207M 88M Sep/2025
Neurocrine Biosciences USD 264M 252.7M Sep/2025
Novartis USD 3.54B 216M Sep/2025
PTC Therapeutics USD 23.32M 7.83M Sep/2025
Regeneron Pharmaceuticals USD 584.6M 63M Dec/2025
Sanofi EUR 3.76B 344M Dec/2025
Sarepta Therapeutics USD 151.45M 1.77M Sep/2025
Takeda JPY 401.15B 184.07B Dec/2025
Ultragenyx Pharmaceutical USD 27.99M 4.99M Sep/2025
Vertex Pharmaceuticals USD 414.8M 7.3M Sep/2025
Xencor USD 61.66M 50.95M Jun/2025